Seoul Economic Daily EnglishCodex · 实盘不做把握 4/10
北京时间·🕒 发布 15:50:16时区推断·⟳ 抓取 16:31:15·⚡ 决策 07-23 18:12:27 +1h41m·96.1 天前
韩国多家公司披露回购注销、分红、发债、业绩和小额合同等例行公告
本条是多家公司例行披露合集，包含回购注销、分红、发债、业绩、供货合同和融资等不同方向事项，缺少单一主线交易。
📄 原文Seoul Economic Daily English↗ 原文
Corporate Disclosures
▲ Shinhan Financial Group (055550.KS) = Decided to cancel 6,698,565 treasury shares. ▲ Hana Financial Group (086790.KS)…
不做 Shinhan Financial Group（055550.KS）
库存股注销为股东回报利好，但缺少规模弹性和未定价证据，单独交易edge不足。
不做 Hana Financial Group（086790.KS）
中期分红属于例行资本回报，未形成短周期超预期交易催化。
不做 KB Financial Group（105560.KS）
2700亿韩元混合资本证券发行方向混合，增强资本同时增加融资成本，不做。
不做 Mirae Asset Securities（006800.KS）
注销普通股和优先股偏利好，但缺少相对市值和总股本的重大性核查，且为披露合集中的常规资本动作。
不做 Samsung Biologics（207940.KS）
二季度收入和营业利润同比增长，但未给一致预期差异；财报类缺少超预期证据不追。
不做 T&L（340570.KQ）
送股不改变企业价值，本身不是经营或现金流催化。
另有 4 腿,见展开详情。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
其余 4 腿
不做 Nano CMS（247660.KQ）
12亿韩元供应合同金额偏小且未核实占营收比例，不足以形成事件交易。
不做 The Pinkfong Company（403850.KQ）
50亿韩元回购信托偏利好但金额有限，缺少足够短线重定价空间。
不做 Seculetter（418250.KQ）
上市资格审查改善计划仍是风险处置事项，方向和执行结果不确定。
不做 AriBio Lab（261780.KQ）
20亿韩元第三方配股补充资金但有摊薄，方向混合且金额不足。
研究档案
🔎 新鲜度:最早出现 2026-07-23 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 本条是多家公司例行披露合集，包含回购注销、分红、发债、业绩、供货合同和融资等不同方向事项，缺少单一主线交易。
- Samsung Biologics二季度收入1.3209万亿韩元、营业利润5864亿韩元，LS Electric收入1.577万亿韩元、营业利润1785亿韩元，但正文未给一致预期差异，不能确认业绩超预期。
- Nano CMS的12亿韩元颜料供应合同、Pinkfong 50亿韩元回购信托、AriBio Lab 20亿韩元定增等金额偏小或方向混合，不足以构成高胜率事件交易。
主要风险
- 业绩和资本操作事项可能已按财报日历被预期，缺少超预期和价格反应证据。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 1,413 字
▲ Shinhan Financial Group (055550.KS) = Decided to cancel 6,698,565 treasury shares.
▲ Hana Financial Group (086790.KS) = Hana Securities decided on an interim dividend of 886.26 won per share.
▲ KB Financial Group (105560.KS) = Decided to issue 270 billion won in private hybrid securities.
▲ Mirae Asset Securities (006800.KS) = Decided to cancel 16,545,829 common shares and 9,850,467 preferred shares.
▲ Samsung Biologics (207940.KS) = Second-quarter consolidated revenue of 1.3209 trillion won (up 30.2% year-on-year) and operating profit of 586.4 billion won (up 22.9%).
▲ LS Electric = Second-quarter consolidated revenue of 1.577 trillion won (up 32.2%) and operating profit of 178.5 billion won (up 64.4%).
▲ T&L (340570.KQ) = Decided on a bonus issue of 7,942,120 common shares.
▲ Neuromeka (348340.KQ) = Final issue price for the rights offering set at 24,550 won.
▲ SungEel HiTech (365340.KQ) = Appointed Lee Dong-seop as a new inside director at an extraordinary shareholders' meeting.
▲ Nano CMS (247660.KQ) = Signed a pigment supply contract worth 1.2 billion won.
▲ The Pinkfong Company (403850.KQ) = Signed a 5 billion won treasury stock acquisition trust agreement with Samsung Securities.
▲ Seculetter (418250.KQ) = Announced an improvement plan related to a substantive review of listing eligibility.
▲ AriBio Lab (261780.KQ) = Decided on a 2 billion won third-party allotment rights offering.
▲ Hana Financial Group (086790.KS) = Hana Securities decided on an interim dividend of 886.26 won per share.
▲ KB Financial Group (105560.KS) = Decided to issue 270 billion won in private hybrid securities.
▲ Mirae Asset Securities (006800.KS) = Decided to cancel 16,545,829 common shares and 9,850,467 preferred shares.
▲ Samsung Biologics (207940.KS) = Second-quarter consolidated revenue of 1.3209 trillion won (up 30.2% year-on-year) and operating profit of 586.4 billion won (up 22.9%).
▲ LS Electric = Second-quarter consolidated revenue of 1.577 trillion won (up 32.2%) and operating profit of 178.5 billion won (up 64.4%).
▲ T&L (340570.KQ) = Decided on a bonus issue of 7,942,120 common shares.
▲ Neuromeka (348340.KQ) = Final issue price for the rights offering set at 24,550 won.
▲ SungEel HiTech (365340.KQ) = Appointed Lee Dong-seop as a new inside director at an extraordinary shareholders' meeting.
▲ Nano CMS (247660.KQ) = Signed a pigment supply contract worth 1.2 billion won.
▲ The Pinkfong Company (403850.KQ) = Signed a 5 billion won treasury stock acquisition trust agreement with Samsung Securities.
▲ Seculetter (418250.KQ) = Announced an improvement plan related to a substantive review of listing eligibility.
▲ AriBio Lab (261780.KQ) = Decided on a 2 billion won third-party allotment rights offering.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。